Hepatitis Monthly

Published by: Kowsar

Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting Antivirals

Khashayar Hesamizadeh 1 , 2 , Heidar Sharafi 1 , 2 , Mohammad Saeid Rezaee-Zavareh 1 , 3 , Bita Behnava 1 , 2 and Seyed Moayed Alavian 1 , 2 , *
Authors Information
1 Middle East Liver Disease (MELD) Center, Tehran, IR Iran
2 Baqiyatallah Research Center for Gastroenterology and Liver Diseases (BRCGL), Baqiyatallah University of Medical Sciences, Tehran, IR Iran
3 Students’ Research Committee, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
Article information
  • Hepatitis Monthly: April 01, 2016, 16 (4); e37089
  • Published Online: April 18, 2016
  • Article Type: Review Article
  • Received: February 12, 2016
  • Accepted: February 21, 2016
  • DOI: 10.5812/hepatmon.37089

To Cite: Hesamizadeh K, Sharafi H, Rezaee-Zavareh M S, Behnava B, Alavian S M. et al. Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting Antivirals, Hepat Mon. 2016 ;16(4):e37089. doi: 10.5812/hepatmon.37089.

Abstract
Copyright © 2016, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
Acknowledgements
Footnotes
References
  • 1. Wen Y, Zheng YX, Tan DM. A Comprehensive Long-Term Prognosis of Chronic Hepatitis C Patients With Antiviral Therapy; A Meta-Analysis of Studies From 2008 to 2014. Hepat Mon. 2015; 15(5)[DOI]
  • 2. Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat. 2014; 21 Suppl 1: 34-59[DOI][PubMed]
  • 3. Hatzakis A, Chulanov V, Gadano AC, Bergin C, Ben-Ari Z, Mossong J, et al. The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2. J Viral Hepat. 2015; 22 Suppl 1: 26-45[DOI][PubMed]
  • 4. Sibley A, Han KH, Abourached A, Lesmana LA, Makara M, Jafri W, et al. The present and future disease burden of hepatitis C virus infections with today's treatment paradigm - volume 3. J Viral Hepat. 2015; 22 Suppl 4: 21-41[DOI][PubMed]
  • 5. Kamal-Yanni M. Hepatitis C drug affordability. Lancet Glob Health. 2015; 3(2)-4[DOI][PubMed]
  • 6. Pourhoseingholi MA, Ashtari S, Alavian SM. Sofosbuvir vs. Combination of Pegylated Interferon and Ribavirin; How Much Shall Pay for Iranian Patients? Hepat Mon. 2014; 14(11)[DOI][PubMed]
  • 7. Adinolfi LE, Guerrera B. All-oral interferon-free treatments: The end of hepatitis C virus story, the dream and the reality. World J Hepatol. 2015; 7(22): 2363-8[DOI][PubMed]
  • 8. Tong MJ, Reddy KR, Lee WM, Pockros PJ, Hoefs JC, Keeffe EB, et al. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group. Hepatology. 1997; 26(3): 747-54[DOI][PubMed]
  • 9. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 1998; 352(9138): 1426-32[PubMed]
  • 10. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 358(9286): 958-65[PubMed]
  • 11. Jacobson IM, Gonzalez SA, Ahmed F, Lebovics E, Min AD, Bodenheimer HJ, et al. A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C. Am J Gastroenterol. 2005; 100(11): 2453-62[DOI][PubMed]
  • 12. Lee SS, Bain VG, Peltekian K, Krajden M, Yoshida EM, Deschenes M, et al. Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice. Aliment Pharmacol Ther. 2006; 23(3): 397-408[DOI][PubMed]
  • 13. Sharafi H, Alavian SM. IL28B polymorphism, Explanation for Different Responses to Therapy in Hepatitis C Patients. Hepat Mon. 2011; 11(12): 958-9[DOI][PubMed]
  • 14. Haj-Sheykholeslami A, Keshvari M, Sharafi H, Pouryasin A, Hemmati K, Mohammadzadehparjikolaei F. Interferon-lambda polymorphisms and response to pegylated interferon in Iranian hepatitis C patients. World J Gastroenterol. 2015; 21(29): 8935-42[DOI][PubMed]
  • 15. Behnava B, Sharafi H, Keshvari M, Pouryasin A, Mehrnoush L, Salimi S, et al. The Role of Polymorphisms Near the IL28B Gene on Response to Peg-Interferon and Ribavirin in Thalassemic Patients With Hepatitis C. Hepat Mon. 2016; 16(1)[DOI]
  • 16. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, et al. Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med. 1986; 315(25): 1575-8[DOI][PubMed]
  • 17. Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010; 376(9742): 705-16[DOI][PubMed]
  • 18. McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010; 362(14): 1292-303[DOI][PubMed]
  • 19. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013; 368(20): 1878-87[DOI][PubMed]
  • 20. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013; 368(20): 1867-77[DOI][PubMed]
  • 21. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014; 370(20): 1889-98[DOI][PubMed]
  • 22. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014; 370(16): 1483-93[DOI][PubMed]
  • 23. Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014; 370(21): 1983-92[DOI][PubMed]
  • 24. Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ben Ari Z, Zhao Y, et al. Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. Ann Intern Med. 2015; 163(1): 1-13[DOI][PubMed]
  • 25. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014; 370(3): 211-21[DOI][PubMed]
  • 26. Kwo P, Gitlin N, Nahass R, Bernstein D, Etzkorn K, Rojter S, et al. Simeprevir Plus Sofosbuvir (12 and 8 Weeks) in HCV Genotype 1-Infected Patients Without Cirrhosis: OPTIMIST-1, a Phase 3, Randomized Study. Hepatology. 2016; [DOI][PubMed]
  • 27. Edlin BR, Winkelstein ER. Can hepatitis C be eradicated in the United States? Antiviral Res. 2014; 110: 79-93[DOI][PubMed]
  • 28. Rezaee Zavareh MS, Alavian SM. Occult Hepatitis C Infection Should Be More Noticed With New Treatment Strategies. Hepat Mon. 2015; 15(11)[DOI][PubMed]
  • 29. Rezaee-Zavareh MS, Hadi R, Karimi-Sari H, Hossein Khosravi M, Ajudani R, Dolatimehr F, et al. Occult HCV Infection: The Current State of Knowledge. Iran Red Crescent Med J. 2015; 17(11)[DOI][PubMed]
  • 30. Waheed Y. Hepatitis C eradication: A long way to go. World J Gastroenterol. 2015; 21(43): 12510-2[DOI][PubMed]
  • 31. Sears DM, Cohen DC, Ackerman K, Ma JE, Song J. Birth cohort screening for chronic hepatitis during colonoscopy appointments. Am J Gastroenterol. 2013; 108(6): 981-9
  • 32. el-Sadawy M, Ragab H, el-Toukhy H, el-Mor Ael L, Mangoud AM, Eissa MH, et al. Hepatitis C virus infection at Sharkia Governorate, Egypt: seroprevalence and associated risk factors. J Egypt Soc Parasitol. 2004; 34(1 Suppl): 367-84[PubMed]
  • 33. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006; 144(10): 705-14[PubMed]
  • 34. Hagan LM, Schinazi RF. Best strategies for global HCV eradication. Liver Int. 2013; 33 Suppl 1: 68-79[DOI][PubMed]
  • 35. Graham CS, Swan T. A path to eradication of hepatitis C in low- and middle-income countries. Antiviral Res. 2015; 119: 89-96[DOI][PubMed]
  • 36. Ippolito G, Capobianchi MR, Lanini S, Antonelli G. Is hepatitis C virus eradication around the corner only 25 years after its discovery? Int J Antimicrob Agents. 2015; 45(2): 111-2[DOI][PubMed]
  • 37. Gish RG, Afdhal NH, Dieterich DT, Reddy KR. Management of hepatitis C virus in special populations: patient and treatment considerations. Clin Gastroenterol Hepatol. 2005; 3(4): 311-8[PubMed]
  • 38. Anwar N, Sherman KE. HCV treatment of special populations: HIV coinfected, liver transplant, and renal failure. Clin Liver Dis. 2014; 4(4): 80-3
  • 39. Flamm SL. Hepatitis C Virus Infection in Special Populations. Gastroenterol Hepatol. 2013; 9(12): 823
  • 40. Karageorgopoulos DE, Allen J, Bhagani S. Hepatitis C in human immunodeficiency virus co-infected individuals: Is this still a "special population"? World J Hepatol. 2015; 7(15): 1936-52[DOI][PubMed]
  • 41. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2006; 44(1 Suppl)-9[DOI][PubMed]
  • 42. Sulkowski M, Hezode C, Gerstoft J, Vierling JM, Mallolas J, Pol S, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015; 385(9973): 1087-97[DOI][PubMed]
  • 43. Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis. 2013; 13(7): 597-605[DOI][PubMed]
  • 44. Panel on Clinical Practices for Treatment of H. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. February 5, 2001. HIV Clin Trials. 2001; 2(3): 227-306[DOI][PubMed]
  • 45. Osinusi A, Townsend K, Kohli A, Nelson A, Seamon C, Meissner EG, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA. 2015; 313(12): 1232-9[DOI][PubMed]
  • 46. Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, et al. Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med. 2015; 373(8): 714-25[DOI][PubMed]
  • 47. Samimi-Rad K, Shahbaz B. Hepatitis C virus genotypes among patients with thalassemia and inherited bleeding disorders in Markazi province, Iran. Haemophilia. 2007; 13(2): 156-63[DOI][PubMed]
  • 48. Sandoughdaran S, Alavian SM, Sharafi H, Behnava B, Salimi S, Mehrnoush L, et al. Efficacy of Prolonged Treatment With Pegylated Interferon (Peg-IFN) and Ribavirin in Thalassemic Patients With Hepatitis C Who Relapsed After Previous Peg-IFN-Based Therapy. Hepat Mon. 2015; 15(1)[DOI][PubMed]
  • 49. Tabatabaei SV, Alavian SM, Keshvari M, Behnava B, Miri SM, Karimi Elizee P, et al. Low dose ribavirin for treatment of hepatitis C virus infected thalassemia major patients; new indications for combination therapy. Hepat Mon. 2012; 12(6): 372-81[DOI][PubMed]
  • 50. Zoulim F, Bailly F. New approaches to the management of hepatitis C in haemophilia in 2012. Haemophilia. 2012; 18 Suppl 4: 28-33[DOI][PubMed]
  • 51. European Association for Study of L. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015; 63(1): 199-236[DOI][PubMed]
  • 52. Stedman CA, Hyland RH, Ding X, Pang PS, McHutchison JG, Gane EJ. Once daily ledipasvir/sofosbuvir fixed-dose combination with ribavirin in patients with inherited bleeding disorders and hepatitis C genotype 1 infection. Haemophilia. 2015; [DOI][PubMed]
  • 53. Goodkin DA, Bieber B, Gillespie B, Robinson BM, Jadoul M. Hepatitis C infection is very rarely treated among hemodialysis patients. Am J Nephrol. 2013; 38(5): 405-12[DOI][PubMed]
  • 54. Hill L. Hepatitis C Virus Direct-Acting Antiviral Drug Interactions and Use in Renal and Hepatic Impairment. Top Antivir Med. 2015; 23(2): 92-6[PubMed]
  • 55. Fontana RJ, Hughes EA, Bifano M, Appelman H, Dimitrova D, Hindes R, et al. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant. 2013; 13(6): 1601-5[DOI][PubMed]
  • 56. Coilly A, Roche B, Duclos-Vallee JC, Samuel D. Optimal therapy in hepatitis C virus liver transplant patients with direct acting antivirals. Liver Int. 2015; 35 Suppl 1: 44-50[DOI][PubMed]
  • 57. Curry MP, Forns X, Chung RT, Terrault NA, Brown RJ, Fenkel JM, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology. 2015; 148(1): 100-107 e1[DOI][PubMed]
  • 58. Roingeard P. Is hepatitis C virus eradication a realistic objective n the absence of a prophylactic vaccine? Liver Int. 2016; [DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments